|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities
This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.
Hemophilia is a complex disease state that requires a working knowledge of the many factors that influence treatment. This activity will review hemophilia as it pertains to specialty pharmacy. Treatment choices for hemophilia A and B are discussed. Inhibitor development will be explained including diagnosis and treatment options as well as the impact to therapy. Specific considerations in dispensing factor are outlined and new and pipeline therapies are reviewed.
The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:
- Express a general understanding of the etiology of hemophilia.
- Recognize appropriate treatment options based on specific hemophilia diagnosis.
- Describe how the development of an inhibitor impacts treatment considerations.
- Discuss variables in dispensing factor prescriptions.
- Recognize Hemlibra’s place in therapy.
- Review new and pipeline treatment options.
Erin Mellerski, PharmD, CSP
Cottrill’s Pharmacy, Inc.
Orchard Park, NY
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Mellerski has no relevant commercial or financial relationships to disclose.
Release Date: 11-1-2019
Expiration Date: 11-19-2022
This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-511-H01-P has been assigned to this knowledge-based home-study CE activity. This activity is approved for 0.5 contact hour (0.05 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.